, Impact de l'utilisation du test Oncotype DX sur les décisions de chimiothérapie adjuvante dans le cancer du sein hormono-dépendant HER2 négatif : une expérience française Auteurs, Le manuscrit original a été soumis et est actuellement en révision dans la revue Bulletin du Cancer

E. Senkus, S. Kyriakides, S. Ohno, F. Penault-llorca, P. Poortmans et al., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. sept, vol.26, issue.5, pp.8-30, 2015.

E. Chéreau, C. Coutant, J. Gligorov, B. Lesieur, M. Antoine et al., Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival, Clin Breast Cancer, vol.11, issue.1, pp.46-51, 2011.

, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, vol.365, issue.9472, pp.1687-717, 2005.

S. Paik, G. Tang, S. Shak, C. Kim, J. Baker et al., Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, vol.24, issue.23, pp.3726-3760, 2006.

A. Vataire, E. Laas, S. Aballe´a, J. Gligorov, R. Rouzier et al., Analyse coût efficacité d'un test prédictif de la chimiothérapie dans le cancer du sein (Oncotype DX) en France, Bull Cancer, vol.99, issue.10, pp.907-921, 2012.

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, vol.351, issue.27, pp.2817-2843, 2004.

K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, R. B. Livingston et al., Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, vol.11, issue.1, pp.55-65, 2010.

J. A. Sparano, R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain et al.,

, Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer, N Engl J Med, vol.12, issue.2, p.11121, 2018.

, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2005.

J. Gligorov, X. B. Pivot, W. Jacot, H. L. Naman, D. Spaeth et al., Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study, Oncologist. août, vol.20, issue.8, 2015.

J. Albanell, C. Svedman, J. Gligorov, S. Holt, G. Bertelli et al., Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer, Eur J Cancer, vol.66, p.10413, 2016.

M. G. Rath, L. Uhlmann, M. Fiedler, J. Heil, M. Golatta et al., Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up-a case-control study, Arch Gynecol Obstet. févr, vol.297, issue.2, p.4437, 2018.

C. Dreyfus, M. Ballester, J. Gligorov, P. Agranat, M. Antoine et al., Impact d'un test de signature génomique en sénologie sur les décisions en réunion de concertation pluridisciplinaire: une expérience française, Gynecologie Obstetrique & Fertilite, vol.12, issue.43, p.7805, 2015.

D. M. Bello, C. Russell, D. Mccullough, M. Tierno, and M. Morrow, Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology, Ann Surg Oncol, vol.25, issue.10, p.28849, 2018.

K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, R. B. Livingston et al., Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol. janv, vol.11, issue.1, p.5565, 2010.

U. Nitz, O. Gluz, M. Christgen, R. E. Kates, M. Clemens et al., Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, Breast Cancer Res Treat, vol.165, issue.3, p.57383, 2017.

E. P. Mamounas, C. A. Russell, A. Lau, M. P. Turner, and K. S. Albain, Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with nodepositive breast cancer in the genomic era, NPJ Breast Cancer, vol.4, p.27, 2018.

, Essai clinique cancer Sein/Sein clos aux inclusions

D. Sur,

A. D. Williams, S. A. Reyes, R. L. Arlow, J. Tchou, D. Cruz et al., Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged <50 Years versus 50 Years, and Trends Over Time, Ann Surg Oncol, vol.25, issue.10, p.287583, 2018.

E. Senkus, S. Kyriakides, S. Ohno, F. Penault-llorca, P. Poortmans et al., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. sept, vol.26, issue.5, 2015.

R. Stuart-harris, C. Caldas, S. E. Pinder, and P. Pharoah, Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients, Breast. août, vol.17, issue.4, p.32334, 2008.

E. Luporsi, F. André, F. Spyratos, P. Martin, J. Jacquemier et al., Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat. avr, vol.132, issue.3, p.895915, 2012.

G. Viale, A. Giobbie-hurder, M. M. Regan, A. S. Coates, M. G. Mastropasqua et al., Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole, J Clin Oncol. 1 déc, vol.26, issue.34, p.556975, 2008.

F. Penault-llorca, F. André, C. Sagan, M. Lacroix-triki, Y. Denoux et al., Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer, J Clin Oncol. 10 juin, vol.27, issue.17, p.280915, 2009.

V. Özmen, A. Atasoy, E. Gökmen, M. Özdoan, N. Güler et al., Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey, J Breast Health. 1 juill, vol.12, issue.3, p.10711, 2016.

K. Singh, X. He, E. T. Kalife, S. Ehdaivand, Y. Wang et al., Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results, Breast Cancer Res Treat. févr, vol.168, issue.1, p.2934, 2018.

L. N. Chaudhary, Z. Jawa, A. Szabo, A. Visotcky, and C. R. Chitambar, Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score, Hematol Oncol Stem Cell Ther. juin, vol.9, issue.2, p.4854, 2016.

Y. Hou, G. Tozbikian, D. L. Zynger, and Z. Li, Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay), Am J Clin Pathol. 1 juin, vol.147, issue.6, p.5418, 2017.

B. Yeo, L. Zabaglo, M. Hills, A. Dodson, I. Smith et al., Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study, Br J Cancer. 28 juill, vol.113, issue.3, p.3905, 2015.